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Abstract
Rationale Over the last decade, Asian ginseng (Panax
ginseng) has been shown to improve aspects of human
cognitive function. American ginseng (Panax quinquefolius)
has a distinct ginsenoside profile from P. ginseng, promising
cognitive enhancing properties in preclinical studies and
benefits processes linked to human cognition.
Objectives The availability of a highly standardised extract
of P. quinquefolius (Cereboost™) led us to evaluate its
neurocognitive properties in humans for the first time.
Methods This randomised, double-blind, placebo-controlled,
crossover trial (N=32, healthy young adults) assessed the
acute mood, neurocognitive and glycaemic effects of three
doses (100, 200 400 mg) of Cereboost™ (P. quinquefolius
standardised to 10.65% ginsenosides). Participants' mood,
cognitive function and blood glucose were measured 1, 3
and 6 h following administration.
Results There was a significant improvement of working
memory (WM) performance associated with P. quinquefo-
lius. Corsi block performance was improved by all doses at
all testing times. There were differential effects of all doses
on other WM tasks which were maintained across the testing
day. Choice reaction time accuracy and ‘calmness’ were
significantly improved by 100 mg. There were no changes in
blood glucose levels.
Conclusions This preliminary study has identified robust
working memory enhancement following administration of
American ginseng. These effects are distinct from those of
Asian ginseng and suggest that psychopharmacological
properties depend critically on ginsenoside profiles. These
results have ramifications for the psychopharmacology of
herbal extracts and merit further study using different
dosing regimens and in populations where cognition is
fragile.
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Introduction
‘Ginseng’ usually refers to extracts of plants from the
Panax genus of the Araliaceae family. Extracts of ginseng
have been used for millennia in Traditional Chinese
Medicine for the prevention and treatment of a variety of
diseases, and as general health elixirs and performance
enhancers (including in the neurocognitive area). Empirical
studies have attributed these effects to the action of a group
of ginseng-specific saponins known as ginsenosides. There
is a growing body of evidence to support Panax ginseng
(Asian ginseng) as a cognitive enhancer; Panax quinquefo-
lius (American ginseng) is another prominent species with a
ginsenosides profile distinct to that of P. ginseng. Tradi-
tional use of American ginseng and, more importantly,
preclinical efficacy studies coupled with the development
of a highly standardised extract prompted us to assess its
potential cognition-enhancing properties, which have not
hitherto been investigated in humans.
Regarding the neurocognitive effects of ginseng, a series
of previous studies has assessed the behavioural effects of
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administration of P. ginseng on cognition in young healthy
individuals (Kennedy and Scholey 2003; Kennedy et al.
2001a, b, 2002; Scholey and Kennedy 2002) where P.
ginseng differentially improved scores on a ‘secondary
memory’ factor (a composite of four memory tasks). In the
first study, doses of 200, 400 and 600 mg Ginseng (G115)
were administered. Enhancement of ‘secondary memory’
was found following 400mg at four post-dose testing sessions
while the lower and higher dosage reduced performance on
the ‘speed of attention’ factor (Kennedy et al. 2001b).
Kennedy et al. (2002) replicated the finding that 400 mg
dosage improved ‘secondary memory’. In a different study,
assessing combinations of Ginseng and Ginkgo (ratio
100:60) at dosages of 320, 640, 960 mg, a similar pattern
was observed (Kennedy et al. 2001a). There was improved
performance of secondary memory following 960 mg, with
reduced performance on speed of attention for the other
dosages (320 and 640 mg). A later study assessed the effects
of 200 and 400 mg Ginseng during sustained cognitive
demand—repeated cycles of Serial Threes, Serial Sevens and
the Bakan Rapid Visual Information Processing (RVIP) task.
Serial Sevens performance was improved by the 200 mg
dose (Reay et al. 2005); in a follow-up study, the same dose
improved Serial Threes and RVIP performance (Reay et al.
2006). It appears that P. ginseng or its constituents are
capable of producing tangible cognitive enhancing effects
and that 200–400 mg appears to be the optimal dose range
for young healthy adults when administered acutely prior to
a cognitive test.
The constituents of the Panax genus which are thought to
contribute to its bioactivity are the ginsenoside saponins.
Ginsenosides can be classified into three groups on the basis
of their chemical structure (Tachikawa et al. 1999); the
Panaxadiol group (Rb1, Rb2, Rb3, Rc etc.), Panaxatriol
group (Re, Rf, Rg1, Rg2, Rh1), and the oleanolic acid
group (e.g. Ro). Many of these ginsenosides have been
isolated and evaluated for pharmacological effects relevant
to cognition. They have been reported to exert effects on the
cholinergic system; isolated Rb1 was observed to both
increase synaptosomal choline uptake, and stimulate acetyl-
choline release (Benishin 1992; Benishin et al. 1991).
Furthermore, Salim et al. (1997) found that in Rb1 increased
expression of rat brain choline acetyltransferase as well as
nerve growth factor messenger RNA. Ginsenosides Rg1 and
Rb1 elicit marked alterations in brain serotonin concen-
trations (Zhang et al. 1990). Other ginsenosides may affect
specific physiological mechanisms, including corticosterone
secretion by Rd (Hiai et al. 1983), inhibition of synapto-
somal uptake of norepinephrine, dopamine, serotonin and
GABA by Rd and Re (Tsang et al. 1985). These physiolog-
ical effects are not straightforward, for example two types of
in vivo modulation of long-term potentiation (LTP) in the rat
hippocampal formation by Rb1 have been observed (Abe et
al. 1994). Neutral Rb1 attenuated the LTP induced by a
strong stimulus train only, whereas as slightly different (also
naturally occurring) variant malonyl-Rb1 facilitated genera-
tion of LTP induced by a weaker stimulation only.
The most widely used standardised Ginseng extract (dis-
cussed above), both commercially and for research purposes, is
G115, a concentrated aqueous extract, which is standardised to
contain an invariable 4% ginsenosides (Soldati and Sticher
1980). However ginsenoside expression is substantially
higher in P. quinquefolius (American Ginseng) than P.
ginseng (Zhu et al. 2004). To date there has been surprisingly
little research evaluating potential cognitive enhancement by
whole extract P. quinquefolius. One study observed that
scopolamine-associated spatial learning impairment in rats
was partially reversed by P. quinquefolius, which also
increased choline uptake in synaptosomal preparations
(Sloley et al. 1999). However despite established associations
between memory and cholinergic function and despite its
high ginsenoside content, studies into the psychogenic
benefits of P. quinquefolius in humans have not previously
been conducted.
Although members of the Panax genus contain many
saponins in common P. quinquefolius has its own character-
istic profile, in this case with high expression of the
ginsenoside Rb1. The extract used in the present study
contains 11.65% ginsenosides—Rb1 (5.68%), Re (2.05%),
Rc (1.86%), Rd (1.47%), Rb2 (0.29%), Rg1 (0.27%).
The above provides sufficient evidence to suggest that P.
quinquefolius may improve cognitive function with similar
or greater benefits than P. ginseng. Given that P. ginseng
has been shown to be most efficacious as a cognitive
enhancer at 200–400 mg in young healthy individuals, the
present study investigated the effect of P. quinquefolius at
similar ginsenoside levels.
The lack of standardised extracts has delayed the progress
of herbal medicine research considerably, including in the
psychopharmacology domain (Scholey et al. 2005). Indeed
the consistent cognitive results obtained with P. ginseng are
partly attributable to the use of a highly standardised extract
(G115). The availability of a standardised American ginseng
extract (Cereboost™) along with evidence of efficacy from
the above studies has allowed us to start a systematic
assessment of its neurocognitive effects. The first study in
this series is a controlled dose-ranging study of cognitive and
mood effects in healthy young adults. Another well-
documented effect of P. quinquefolius is its action on blood
glucose. P. quinquefolius appears to have significant hypo-
glycaemic action in rodents (Martinez and Staba 1984;
Oshima et al. 1987). In humans, P. quinquefolius also
reduced blood glucose levels following a 25-g glucose
challenge in both diabetic patients who had ingested 300,
600 and 900 mg (Vuksan et al. 2000a,b) and non diabetics
administered 100, 200 and 300 mg (Vuksan et al. 2000a,
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2001). There is growing interest in the relationship between
blood glucose and cognitive function. In particular the rate at
which blood glucose levels fall during testing can correlate
with better cognitive performance (Donohoe and Benton
1999a; Kennedy and Scholey 2000). The present study
therefore also assessed the effect of P. quinquefolius extract
on blood glucose in healthy young adults.
Method
Design
The study followed a randomised, double-blind, placebo-
controlled crossover methodology. It used multi-dose,
multiple-testing-times with a 7-day washout period between
treatments.
Participants
Thirty two participants (16 female) were recruited via
advertisements in local newspapers and university bulletin
boards . Ages ranged from 18 to 40 years (M=25.2, SD=
4.97). All participants reported that they were in good
health, not taking any drugs or medications (excluding the
contraceptive pill), had no known food allergies and were
non smokers.
Volunteers completed an initial health screening question-
naire which excluded participants with a number of medical
conditions (e.g. diabetes, hypoglycaemia, psychiatric disor-
ders, epilepsy and gastrointestinal disorders) or who were
taking prescribed medications, were pregnant or lactating.
They were advised to refrain from taking any vitamins, other
herbal supplements and over the counter medicines for the
whole period of study. On the testing days, participants were
advised to abstain from consuming alcohol, caffeine products
and energy drinks. They were required to eat a light breakfast
(toast or cereal) at least 2 h before the onset of the experiment
and were provided with sandwich for lunch (with either
chicken and salad, or cheese and salad), the same foods were
consumed on each study day. The study, which was conducted
according to the Declaration of Helsinki, was approved by the
Swinburne University Human Research Ethics Committee
and all participants gave written informed consent. Volunteers
received AU $200 for their participation.
Treatments
A commercial extract of P. quinquefolius Cereboost™
contained a standardised 11.65% ginsenosides was prepared
and provided by Naturex as detailed below. This was used
to prepare opaque capsules containing 0 mg, 100 mg and
200 mg Cereboost™ with maltodextrose as excipient.
Encapsulation was performed locally by Thompsons Amcal
Pharmacy, Melbourne. Study day treatments took the form
of two capsules corresponding to a dose of either 0
(placebo), 100, 200 or 400 mg of Cereboost™. In order
to maintain the double-blind, each individual's treatments
were prepared by a disinterested third party who took no
further part in the study.
Extract preparation
The roots of American ginseng (P. quinquefolius) were
collected from the region of Ontario, Canada. The roots
were authenticated using macroscopic, microscopic, and
high performance thin layer chromatography techniques
(Reich and Schibli 2006). The American ginseng extract
was obtained through an industrial process (Cereboost™,
Naturex, USA, Reference: GA505000, Lot number E15/05/
D8). Firstly, the ginseng roots were ground to be between 1/
4 and 1/2 in., and then the ground roots were soaked three
times over 5 h intervals in an ethanol/water (75/25, v/v)
solution at 40°C. After filtration, the clarified solution was
concentrated under vacuum at 45°C. The three pools were
combined and concentrated again until the total solids on dry
basis were around 60%. This is the Native Extract, which
was then mixed with maltodextrine as a carrier and spray-
dried to obtain a fine powder. The moisture content in the
extract was less than 5%. After extraction, the sample was
analyzed for its content of pesticides (USP 2008) and heavy
metals (method 993.14, AOAC 2005) at Covance Labora-
tories (Madison, WI, USA) for compliance. The American
ginseng extract was confirmed to be below the Maximum
Residue Limits established for pesticides and heavy metals
(Durgnat et al. 2005).
Analysis of ginsenosides
An HPLC method was developed for the quantification of
ginsenosides in the American ginseng extract. To determine
the concentration of ginsenosides, the standards (ginseno-
sides Rg1, Re, Rf, Rb1, Rc, Rb2 and Rd. Sigma-Aldrich,
USA) and the American ginseng extract were dissolved in
methanol. The HPLC system used was a Hewlett Packard
1100 equipped with an UV detector at 203 nm. The
stationary phase used was a Waters Symmetry C18 column
(5 μm, 4.6 mm ID×250 mm, Waters, USA) thermostated at
25°C. The mobile phases were (a) acetonitrile (Sigma-
Aldrich, USA) and (b) water (Milli-Q, USA) running at
1.5 mL/min. A solution of 20% a and 80% b was
maintained for 20 min, and then changed to 22% a and
78% b, following a step gradient to 46% a and 54% b after
45 min, 55% a and 45% b after 50 min, reaching 100% a
after 51 min (total time is 55 min). The system was then re-
equilibrated to the initial composition for 10 min.
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Blood glucose measurement
Blood glucose levels were measured using a MediSense
Optium Xceed Blood Glucose Sensor and disposable
MediSense Blood Glucose Electrodes (MediSense Britain
Ltd., Birmingham, UK). The accuracy and consistency of
MediSense blood glucose sensors has previously been
established (Matthews et al. 1987). Blood samples were
taken using Owen Mumford ‘Unistik 2’ single use capillary
blood sampling devices (Owen Mumford Ltd., Oxford,
UK). Alcohol-soaked Briemarpak skin cleansing swabs
were used for pre-sampling sterilisation.
On each of the four active study days, blood glucose
levels were measured via capillary finger prick at a
baseline, 1-h post-treatment (prior to the commencement
of the first post-dose battery), 3-h post-treatment (before the
commencement of the second post-dose battery) and 6 h
(before the commencement of the third post-dose cognitive
assessment battery) and at the end of the day's visit.
Cognitive measures
The Computerised Mental Performance Assessment System
(COMPASS) battery has been developed to include tests
which have been shown to be sensitive to nutritional
manipulations. The tasks in this study were designed to
allow assessment across the major cognitive domains i.e.
attention, working memory, secondary memory and execu-
tive function. Parallel versions of each of the following
tasks allowed for multiple testing.
Word presentation Words matched for linguistic familiar-
ity, concreteness and frequency were drawn from http://
www.math.yorku.ca/SCS/Online/paivio. Individual words
were presented sequentially on the monitor. Stimulus
duration was 1 s, as was the inter-stimulus interval.
Immediate word recall The participant was allowed 60 s
to write down as many of the words as possible. The
task was scored for number of correct answers, errors
and intrusions and the resulting score was converted into
a percentage.
Picture presentation Twenty line-drawings of everyday
items were presented on the computer screen. Stimulus
duration was 3 s, with a 1 s inter-stimulus duration.
Face presentation Twelve photographic images of the
faces downloaded from the Productive Aging Lab Face
Database http://www.agingmind.cns.uiuc.edu/facedb/
were presented on the computer screen for the participants
to remember. Stimulus duration was 3 s with inter-stimulus
duration of 1 s.
Simple reaction time A series of upwards pointing arrows
appeared in the centre of the screen with a randomly
varying inter-stimulus interval between 1 and 3 s. The
participant pressed the space bar as quickly as possible to
the on screen appearance of each stimulus and response
times were recorded in milliseconds.
Choice reaction time Arrows pointing to the left or right
were presented in the centre of the screen with a randomly
varying inter-stimulus interval of 1–3 s. The volunteer
pressed the corresponding ‘left’ or ‘right’ cursor key on the
computer keyboard as quickly as possible. The task was
scored for accuracy (%) and reaction time (ms).
Four choice reaction time A representation of the four
directional arrow keys on the computer keyboard appeared at
the centre of the screen. Sequentially, single arrows were
illuminated on the screen with the inter-stimulus interval
randomly varying between 1 and 3 s. The participants were
required to make a response as quickly and as accurately as
possible with the corresponding ‘left’, ‘right’, ‘up’ or ‘down’.
The task was scored for accuracy (% correct) and reaction
time (ms).
Stroop colour-word task The Stroop task (MacLeod 1992;
Stroop 1935) is a classic psychological test of interference,
selective attention and response inhibition. In the current
form, four colour blocks (blue, yellow, red and green) were
displayed on the right hand side of the screen. At a given
time interval, words describing one of the four colours
(‘red’, ‘yellow’, ‘green’, blue’) were presented in different
coloured fonts on the left side of the module area. The
participants were instructed to click on colour panels on the
right in order to identify the font colour (e.g. if the word
‘green’ is presented in a blue font, the correct response
would be to click on the blue panel). The task was scored
for accuracy (%) and response times (msec).
Numeric working memory A series of five digits was
presented on the computer screen sequentially for the
participants to hold in their memory. This was followed by a
series of 30 probe digits. The participants indicated whether or
not the digit was from the original series by pressing
corresponding keys labelled ‘yes’ and ‘no’. This was repeated
three further times with different stimulus sets. Reaction times
(ms) and accuracy (% correct) were measured.
Alphabetic working memory This was similar to the numeric
working memory but using letters. A series of five letters
appeared on the screen for participants to remember. After 4 s
the letters disappeared and were followed by a series of 30
probe letters. Participants were instructed to indicate whether
the target letter had appeared in the original list of five letters
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by pressing corresponding ‘yes’ or ‘no’ key as quickly as
possible. The measures were the percentage of the correctly
identified stimuli and the average reaction time (ms).
Corsi blocks The Corsi block-tapping task is a span task
and a visuospatial analogue of the digit span of verbal
working memory (Lezak et al. 1995; Lezak and Loring
2004). A computerised version of the Corsi blocks task was
employed in the study. A series of squares appeared on the
screen. A number of these illuminated sequentially in quasi-
random order. The volunteer then attempted to repeat the
pattern by clicking the boxes in the same order using the
mouse and cursor. The task becomes progressively more
difficult as the number of boxes increases from four upwards.
The task gives a measure of spatial span as well as speed of
responding.
N-back Single letters were presented on the computer
screen (total number of presented letters was 45 with 15
targets to be identified). The volunteers were instructed to
make key presses labelled ‘yes’ or ‘no’ to indicate whether
the digit is the same as the one N previously (e.g. for 1,
back the previous digit; for 3, back the digit three
previously). The task is scored for speed of reaction (ms)
and accuracy (% correct).
Delayed word recall Approximately 20 min after the word
presentation, the participant was allowed 60 s to write down
as many of the items from word presentation as possible.
The task was scored as for immediate word recall.
Delayed word recognition Word recognition was tested by
representation of the words from the original list randomly
interspersed with an equal number of distracter words.
Participants responded either ‘yes’ or ‘no’ by pressing
corresponding key to indicate whether the word had
previously been presented or not. The task was scored for
accuracy (%), and reaction time (ms).
Delayed picture recognition Picture recognition was tested
by the presentation of the original drawings and an equal
number of distracters in random order. Participants
responded either ‘yes’ or ‘no’ by key press in order to
indicate whether the picture had been presented previ-
ously. The task was scored for accuracy (%) and reaction
time (ms).
Delayed face recognition The originally presented faces
were presented along with an equal number of distracters in
random sequence Participants were responded via key
presses to indicate if they recognised the face from the
initial sequence. Accuracy (% errors) and reaction time
(ms) were measured.
Serial sevens subtraction task Computerised versions of
serial subtraction task were implemented (Scholey et al.
2001), here using tests of 2 min duration. For the serial
sevens task participant was required to count backwards in
sevens from a random starting number between 800 and
999, presented on the computer screen, as quickly and
accurately as possible, using the numeric key pad to enter
each response. Each three-digit response was entered via
the numeric key pad with each digit being represented on
the screen by an asterisk. The task was scored for total
number of subtractions and number of errors. In case of
incorrect responses, subsequent responses were scored as
positive if they were correct in relation to the new number.
Serial threes subtraction task The serial threes task was
identical to serial sevens, except that it involved serial
subtraction of threes.
Rapid visual information processing or Bakan task This
task has been widely used to study the cognitive effects of
psychotropic interventions and is sensitive to blood glucose
levels (Donohoe and Benton 1999b) and ginseng (Reay et
al. 2006) as well as cholinergic modulation (Wesnes and
Warburton 1984). A series of digits were presented on the
screen, one at a time, at the rate of 100/min and in quick
succession. The participant monitors the continuous series for
targets of three consecutive odd or three consecutive even
digits. The participant responds to the detection of a target
string by pressing a space bar as quickly as possible. The task
lasted for 3 min, with eight correct target strings being
presented in each minute. The task was scored for percentage
of target strings correctly detected, the average reaction time
(ms) for correct detections, and the number of false alarms.
Mood measures
Visual analogue scales Mood was assessed during each
testing session via visual analogue scales (VAS) incorpo-
rated into the cognitive battery. These included the 16
Bond–Lader VAS (Bond and Lader 1974). These scales
have high reliability and validity (Ahern 1997) and were
originally designed for assessing the mood effects of
anxiolytics and have been subsequently utilised in numerous
pharmacological, psychopharmacological, medical trials and
research programmes assessing dietary manipulations. Par-
ticipants marked their current subjective state by using the
computer mouse to place a mark on sixteen 100 mm VAS
linking pairs of antonyms. From the resultant scores, three
measures are derived: ‘alertness’ (from individual VAS of
alert-drowsy, attentive-dreamy, lethargic-energetic, muzzy-
clearheaded, well-coordinated-clumsy, mentally slow-quick
witted, strong-feeble, interested-bored, incompetent-
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proficient); ‘calmness’ (calm-excited, tense-relaxed); and
‘contentedness’ (contented–discontented, trouble–tranquil,
happy–sad, antagonistic–friendly, withdrawn–sociable).
Two other visual analogue scales assessed stress and
mental fatigue. Using a computer mouse, participants were
required to place a cross along the line of the visual
analogue scale with end points anchored by ‘not at all’ and
‘extremely’ in response to the questions “How (stressed/
mentally fatigued) do you feel right now?” Scores ranged
from 1 to 100 with higher scores reflecting higher subjective
feelings of stress/mental fatigue.
Pencil-and-paper measures
Depression anxiety and stress scale (DASS, Lovibond and
Lovibond 1995) The shortened 21-item version of the DASS
was used to assess three negative affective states of
depression, anxiety and stress on seven-item scales. The
Depression subscale (DASS-D) measures symptoms relating
to dysphoric mood (e.g. sadness), for example ‘I could not
seem to experience any positive feeling at all’. The Anxiety
subscale (DASS-A) assesses symptoms associated with
physiological hyperarousal, for example ‘I felt I was close to
panic’. The Stress subscale (DASS-S) assesses symptoms
associated with nervous arousal, for example ‘I tended to
over-react to situations’. Participants were required to indicate
on a 4-point scale whether each statement applied to them not
at all, to some degree, a considerable degree, or most of the
time. Subscales were calculated by summing the scores of the
appropriate items. Good internal consistency and validity for
the DASS have been found with samples of clinical patients
and non-clinical volunteers (Antony et al. 1998).
State-trait anxiety inventory The State-Trait Anxiety Inven-
tory (STAI) (Spielberger et al. 1983) comprises of two
scales. The ‘State’ (STAI-S) subscale is a widely used
instrument for measuring fluctuating levels of anxiety. The
subscale contains 20 statements (e.g. ‘I am calm’).
Participants rate how much they feel like each statement
at the time of making the response by marking a 4-point
scale ranging from ‘not at all’ to ‘very much so’. The ‘Trait’
(STAI-T) subscale comprises 20 different statements (e.g.
‘Some unimportant thought runs through my mind and
bothers me’). Participants were asked to indicate how they
generally feel on a scale ranging from ‘almost never’
to ‘almost always’. Scores on both sections of the STAI
range from 20 to 80, with higher scores indicating more
anxiety.
Symptom checklist The symptom checklist was developed
at the Brain Sciences Institute specifically for use with
natural medicines and consists of 28 physiological/psycho-
logical problems people might have, e.g. ‘I feel dizzy’, ‘I
have a dry mouth’, ‘I feel anxious more than usual’ (the
items can be found in Stough et al. 2001). Participants
indicated how much the problem had bothered them in the
last 7 days including today using a 5-point scale from ‘not
at all’ to ‘very much so’.
Procedure
On the arrival at the laboratory participants underwent a
health screen, provided morphometric and demographic
data and signed their informed consent.
Each participant was required to attend a total of five
occasions (one practice session and four study days). Testing
days were 7 days apart to ensure a sufficient washout between
conditions.
Testing took place in a suite of dedicated laboratories
with participants visually isolated from each other. They
also wore headphones to further minimise distraction. On
the first visit participants signed their informed consent
followed by a health screen, were familiarised with the
protocol of the study, including the COMPASS computer-
ised test battery, questionnaires and procedures. Data from
the first day were not included in any analysis.
On arrival for their first testing participants were randomly
allocated to a treatment regime using a Latin square design
that counterbalanced the order of treatments across the four
active days. Each study day comprised four identical sessions
using parallel versions of the COMPASS battery. The first was
a pre-dose testing session that established baseline perfor-
mance for that day and was immediately followed by the day's
treatment (0, 100, 200 or 400 mg Cereboost™). Further
testing sessions began at 1, 3 and 6 h following the
consumption of the treatment. Each assessment involved
blood glucose measurements, pencil-and-paper mood scales
and the completion of the COMPASS cognitive battery. A
light lunch was provided at the end of 1 h post-treatment
session (the same for each participant on each study day).
The symptom checklist was completed at the end of the final
testing session of the day.
Statistical analysis
Data analyses were similar to those used in a series of similar
previous acute, dose-ranging studies (Haskell et al. 2007;
Kennedy et al. 2001a, b, 2002; Kennedy et al. 2003; Reay et
al. 2005, 2006; Scholey et al. 2008; Tildesley et al. 2005)
and followed the recommendations of Keppel (1991).
Change-from-baseline scores on study days were com-
puted for each cognitive measure, at each time-point for
every dose. These data were subjected to a General Linear
Model ANOVA with terms fitted to the model for dose
(placebo, 100, 200 and 400 mg), session (1, 3 and 6 h),
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dose×session and participant. The initial omnibus ANOVA
was employed only to determine the MSError for the
appropriate planned comparisons which were performed
using t tests incorporating MSError from the ANOVA
(Keppel 1991).
The primary analysis therefore involved planned compar-
isons of the change-from-baseline scores comparing each of
the active treatments and placebo at each time point utilising t
tests calculated with the mean squares error from the initial
ANOVA as an error term. Given the exploratory nature of
the study no specific adjustment was made for multiple
comparisons, however we reduced the potential for type I
error by implementing a number of safeguards. Firstly, we
utilised an a priori statistical plan which restricted pre-
planned comparisons to measures where there was a
significant main effect of treatment, or a treatment×time
interaction only. Secondly all these analyses were two-tailed,
restricted to planned comparisons and constrained by the
number of conditions minus one (i.e. three) at each time
point. Finally, compared with single time-points differences,
there is an exponentially decreasing probability for signifi-
cant differences at two and three time-points for the same
dose, so here we avoid any interpretation of significant
differences isolated to one time-point (though they are
reported).
Results
The American ginseng extract used in this clinical trial
contained 0.28% of Rg1, 2.06% of Re, 5.69% of Rb1,
1.87% of Rc, 0.29% of Rb2 and 1.48% of Rd. The total
ginsenosides, calculated as the sum of above individual
ginsenosides, represented 11.65% in the American ginseng
extract. As expected, the ginsenoside Rf was not found
(Harkey et al. 2001). The ginsenoside Rf is not present in
American ginseng but it is present in Asian ginseng (P.
ginseng), and is used as a marker to determine adulterations
in American ginseng. The chromatogram of the American
ginseng extract and the structures of its ginsenosides are
presented in Fig. 1.
Initial one-way analyses on each cognitive and mood
measure revealed no significant baseline differences be-
tween conditions confirming that post-treatment effects
were not attributable to differences in baseline performance.
Significant results are presented graphically in Fig. 2.
For Immediate Word Recall there was a significant main
effect of Treatment [F(3,78)=4.41, p=0.006] and a Treat-
ment x Time interaction [F(6,156)=3.183, p=0.006].
Comparisons of each dose at each time point revealed
significant improvements associated with the 200 mg dose
at all three time-points [t=3.206, p=0.003; t=3.313, p=
0.002; t=3.407, p=0.002 at 1 h, 3 h and 6 h respectively].
There were also significant improvements for 400 mg at 1 h
[t=3.15, p=0.004] and 100 mg at 6 h only [t=3.212, p=
0.003].
For Choice Reaction Time accuracy there was a
significant main effect of treatment [F(3,54)=3.223, p=
0.030]. Comparisons of each dose at each time point
revealed significant improvements associated with the
100 mg dose at all three time-points [t=3.03, p=0.006; t=
2.109, p=0.047; t=2.117, p=0.046 at 1 h, 3 h and 6 h
respectively]. There were also significant improvements for
400 mg at 1 h [t=4.60, p<0.001] and both 200 and 100 mg
at 6 h [t=2.066, p=0.048; t=2.533, p=0.017, respectively].
There was a significant main effect of Treatment for
Numeric Working Memory speed [F(3,63)=4.39, p=0.007].
Comparisons of each dose at each time point revealed
significant improvements associated with the 200 mg dose
at all three time-points [t=2.155, p=0.039; t=2.73, p=
0.011; t=3.07, p=0.005 at 1 h, 3 h and 6 h, respectively].
There was a significant main effect of Treatment for speed
of Alphabetic Working Memory [F(3,48)=3.22, p=0.04].
Comparisons of each dose at each time point revealed
significant improvements at all three time-points associated
with the 100 mg [t=2.13, p=0.041; t=2.28; p=0.03; t=
2.09, p=0.045 at 1 h, 3 h and 6 h, respectively] and 400 mg
doses [t=2.24, p=0.033; t=2.17, p=0.038; t=2.20, p=
0.036 at 1 h, 3 h and 6 h, respectively]. There was a
significant main effects of Treatment on mean Corsi block
score [F(3,114)=2.925, p=0.041]. Comparisons of each
dose at each time point revealed significant improvements
at all time-points associated with 100 mg [t=2.18, p=0.037;
t=2.50, p=0.019; t=2.40, p=0.023 at 1 h, 3 h and 6 h,
respectively], 200 mg [t=2.21, p=0.035; t=2.57, p=0.015;
t=2.57, p=0.015 at 1 h, 3 h and 6 h, respectively] and
400 mg [t=2.33, p<0.027; t=2.11, p=0.042; t=3.41, p=
0.002 at 1 h, 3 h and 6 h, respectively].
There was a single effect of treatment on mood. The
Treatment x Time interaction on self-rated calmness was
significant [F6,150=2.345, p=0.034]. Pre-planned compar-
isons of each dose at each time point revealed significant
improvements associated with the 100 mg dose at 3 h and
6 h only [t=3.34, p=0.002; t=3.80, p=0.001, respectively].
There were no significant effects on any other measure.
Discussion
This is first study to evaluate the acute mood and cognitive
effects of P. quinquefolius (American ginseng) extract in
humans. We found treatment-related improvements in cogni-
tive performance and increased calmness in healthy young
adults. Compared to a placebo, all doses of Cereboost™ were
found to improve some aspect of cognition. The present study
did not observe any effect of on blood glucose levels thereby
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ruling out any interpretation of the cognitive facilitation
effects as being due to impact on glucose or insulin-
mediated mechanisms.
All three active doses improved Corsi blocks perfor-
mance compared with placebo at all post-dose time-points
with the most beneficial effects being observed for the
lower two doses. Other than this the most robust effects
were observed for the 200 mg dose, (although all doses
influenced cognition to some degree). Immediate Word
Recall accuracy and numeric working memory speed were
differentially improved by the 200 mg dose at all three
post-dose time-points. Conversely alphabetic working
memory speed was improved at all three time-points
following the 100 and 400 mg doses. Choice Reaction
Fig. 1 a Chromatogram of the
American ginseng (Panax quin-
quefolius) extract. b Structures
of ginsenosides
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Fig. 2 Significant effects of Panax quinquefolius on cognitive
function and mood. Graphs depict mean change-from-baseline scores
following a placebo and 100, 200 and 400 mg of a standardised
extract. Significant differences from placebo at each time point are
indicated (*p<0.05, see text for details)
352 Psychopharmacology (2010) 212:345–356
Time accuracy was significantly improved following both
100 and 400 mg at 1 h post-administration. At 3 h post-
administration 100 mg continued to improve performance,
and at 6 h post-administration choice reaction time accuracy
was significantly improved by all treatment doses compared
with placebo. The differential dose- and time- effects may
indicate differential sensitivity of biological systems to specific
neural substrates affected by ginseng and its constituent
ginsenosides.
Regarding mood effects, compared to placebo 100 mg
Cereboost™ improved self-rated calmness at 3 h and 6 h
following administration. As this is the first study to assess
the effects of this extract on mood, few comparisons can be
drawn with the existing research. However a number of
studies have assessed the effect of P. ginseng on mood
using the same Bond Lader mood scale as the present study
(Kennedy et al. 2001a, b, 2002). Both 200 and 400 mg
reduced alertness at 6 h (Kennedy et al. 2001a) and
calmness at 2.5 and 4 h (Reay et al. 2010). Other studies
have also reported reduced mental fatigue during sustained
mental effort following P. ginseng in healthy young
individuals (Reay et al. 2005, 2006). In the present study
100 mg Cereboost™ was associated with increased
calmness ratings at later time-points. Previous research in
rodents has shown that Ginseng saponins and Ginsenoside
Rb1 inhibit the stress-induced increases in plasma cortico-
sterone (Kim et al. 1998a,b; Luo et al. 1993) later found
that this inhibitory action of Ginseng was blocked by a
co-administered inhibitor of nitric oxide (NO) synthase,
suggesting that ginsenosides may modulate the stress-
induced hypothalamus–pituitary–adrenal response by in-
ducing NO production in the brain. Clearly at present this
interpretation is purely speculative (indeed we found no
effect of ginseng on self-ratings of stress), but may merit
further investigation.
The mechanism(s) by which extracts of Ginseng or
individual components derived from Ginseng exert their
effects on cognition are not known. A number of potentially
complementary effects may be involved. For example
neuroprotective effects of ginsenosides have been demon-
strated in vitro (Rudakewich et al. 2001) and in vivo. Such
effects include protection of hippocampal CA1 neurons,
reduction of infarct area (Zhang and Liu 1996), reduced
lipid peroxidation, scavenging of oxygen free radicals
(Chen et al. 1987) and preservation of local cerebral
glucose utilisation (Choi et al. 1996) following ischaemia
in rodents. Increased NO synthesis has been proposed to
underlie these neuroprotective effects. The enzyme NO
synthase has been shown to be present throughout the brain
with a particular prevalence in the cerebellum and is
reported to be involved in hippocampal LTP (Salemme et
al. 1996) and general memory processes (Prast and Philippu
2001). Kennedy and Scholey (2003) note that it may be
significant that following ginsenoside administration, the
release of NO from endothelial cells has been shown to be
specific to the Panaxatriol rather than the Panaxadiol
ginsenosides (Kang et al. 1995). Jin et al. (1999) suggest
that memory enhancing effects in rodents are restricted to
extracts with a high ratio of Panaxatriol to Panaxadiol
ginsenoside content. Indeed the present study has observed
substantial memory enhancement using the extract Cere-
boost™, which has a high Panaxatriol to Panaxadiol
ginsenoside content (see Fig. 1).
While Ginseng and Ginseng saponins boast an array of
neuroprotective effects it seems unlikely that these attributes
would greatly benefit cognition acutely. It seems more likely
that any neuroprotective effects might be more pronounced in
chronic trauma and/or deficit populations. However the
effects of Ginsengosides are not limited to neuroprotective
effects. As well as increased NO-mediated blood flow (Kim et
al. 1998b), ginsenosides can increase choline uptake (Zhang
et al. 1990), acetylcholine release (Benishin et al. 1991) and
monoamine metabolism (Petkov 1990) all of which may
contribute to acute positive neurocognitive effects.
The data presented here demonstrate enhancement effects
of P. quinquefolius predominantly on working memory
processes (Corsi blocks, and both numeric and alphabetic
working memory). There is also some evidence of positive
effects on short-term verbal declarative memory (immediate
word recall) and attention (choice reaction time). Such
findings tempt speculation about the neuroanatomical loci
of these effects. As well as its well-documented role in long-
term episodic memory (Eichenbaum and Cohen 2001), there
is increasing evidence that the hippocampus may be
involved in working memory (Axmacher et al. 2009)
particularly, as in the tests used here, when multiple items
are processed. However, if the effects here are largely driven
by hippocampal activation we might expect a more
pronounced effect on secondary memory above the enhance-
ment of immediate word recall. Working and short-term
memory systems are thought be localized to parietal,
hippocampal and pre-frontal cerebral circuitry, with the
pre-frontal cortex dealing with higher order working
memory/executive functions including manipulating
working memory (Gabrieli et al. 1998; Goldman-Rakic
et al. 1996). Currently, there is a paucity of data regarding
brain areas involved in the cognition-enhancing of effects
of Ginseng, we hope that neuroimaging studies will soon
reveal which areas are activated by Ginseng during cognitive
processing.
It has been well documented that the cholinergic path-
ways projecting to the cerebral cortex and hippocampus
play a key role in learning and memory. It has also been
argued that the cholinergic system is a specific target for
cognitively enhancing agents (Giovannini et al. 1995). A
number of studies have identified cholinergic properties
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associated with isolated ginsenosides. A direct interaction
between Rg2 and nicotinic receptor subtypes has been
observed (Sala et al. 2002). Moreover Benshin (1992)
demonstrated modulation by Rb1 of acetylcholine release
and reuptake, along with a number of choline uptake sites
in the hippocampus, and to a lesser extent, the cortex. Both
ginsenosides Rg1 (Zhang et al. 1990) and Rb1 (Salim et al.
1997; Zhang et al. 1990) have also been shown to increase
choline acetyltransferase levels in the rat brain.
Scopolamine-induced deficits are attenuated by P. quinque-
folius in rodents (Sloley et al. 1999). Protection against
scopolamine-induced amnesia by P. quinquefolius was most
evident in trials where animals were required to remember
the task learned the previous day. In the same study, it was
observed that Ginseng increased choline uptake into
synaptosomes prepared from rat brain. In the human brain
crude extracts of P. ginseng exhibited an affinity for both
nicotinic and muscarinic receptors in cerebral cortex
membrane (Lewis et al. 1999). As discussed previously,
the P. quinquefolius extract profile has 2–3 times the
ginsenoside content than the more commonly researched
P. ginseng, with the highest expression of Rb1 and Re.
Thus the cholinergic system is one potential central
mechanism of action on the enhancement of memory by
Cereboost™. On the other hand, the RVIP task used here
may been regarded as a prototypical cholinergic task, and
we found no effect of the ginseng extract on this measure.
A second aim of the study was to assess the acute effects
of P. quinquefolius on glucoregulation on young healthy
adults. The results of the present study show that, at least at
the dosages used here American ginseng has no effect on
blood glucose levels. Vuksan et al. (2000a) previously
observed that 300 mg P. quinquefolius lowered blood
glucose levels during a glucose challenge in both healthy
and diabetic subjects. In that study, however, Ginseng
administration lowered blood glucose levels only when
taken 40 min prior to the glucose challenge in healthy
individuals. Conversely, diabetic subjects experienced a fall
in blood glucose either whether Ginseng was administered
40 min prior to, or concurrently with, the glucose challenge,
suggesting that this effect is somewhat more robust in
diabetic subjects (or at least that the temporal aspects are
less important in that population). It is also noteworthy that
in the Vuksan study there was a substantial age difference
between the ‘healthy’ individuals (34±7 year) and the
diabetic individuals (62±7 year) raising the possibility that
the effect of P. quinquefolius on blood glucoregulation is
more robust in older individuals. In the present study the
‘healthy’ individuals were in their mid-20s, somewhat
younger than those in the study by Vuksan's group.
Additionally the largest body of research assessing the
effects of Ginseng on peripheral circulating blood glucose
in humans has tended to investigate chronic administration
(Vuksan et al. 2008; Vuksan et al. 2000b). It would be
of great interest to evaluate glucoregulatory properties
would emerge with chronic dosing using cereboost™,
and any relationship with neurocognitive effects of such a
regimen.
It is worth noting that these findings should be treated
with a degree of caution. Firstly, this is the first investiga-
tion into the neurocognitive effects of American ginseng.
Clearly the study needs at least partial replication possibly
with more focus on specific working memory processes.
Secondly, given the exploratory nature of the study, no
adjustment was made for multiple comparisons (although
we did implement a number of safeguards against conflated
Type 1 error). This follows the recommendations of Keppel
(1991) and is consistent with analyses utilised in a series of
similar, acute dose-ranging studies (Haskell et al. 2007;
Kennedy et al. 2001a, b, 2002; Kennedy et al. 2003; Reay
et al. 2005, 2006; Scholey et al. 2008; Tildesley et al.
2005). We are aware that adjusting the alpha level to allow
for multiple comparisons would have yielded fewer
significant findings. On the other hand this should be
balanced against the observation that for the majority of
outcomes where there were significant differences, these
were at all three time-points (and for Alphabetic Working
Memory and Corsi blocks for two and three doses,
respectively) suggesting that they are unlikely to have
arisen from Type 1 errors.
Overall the findings of the present study were the first to
demonstrate cognitive and mood enhancement following
Cereboost™ administration. Furthermore cognition-
enhancing effects of the extract were observed across a
range of cognitive modalities at a range of dosages. The
lack of glycaemic effects suggest that these effects can
occur independently of changes in blood glucose, at least in
healthy younger populations. Further research is required
assessing the neurocognitive effects of P. quinquefolius in
other populations (e.g. older individuals and those with
cognitive problems) as well as evaluating the neurocogni-
tive effects of chronic administration.
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